Knopp Biosciences LLC today announced the presentation of data from an ongoing, open-label pilot-study of dexpramipexole in hypereosinophilic syndromes (HES) demonstrating hematological responses, symptom improvement, and steroid sparing in a subset of subjects with steroid-dependent HES.
Full results from the completed study, including data from the secondary endpoints and bone marrow studies, will be submitted for publication in a peer-reviewed journal. In the abstract, the NIAID investigators noted, “Dexpramipexole showed remarkable efficacy as a steroid-sparing agent without apparent toxicity in a subset of subjects with steroid-responsive HES.”
Comments are closed.